Freedom Capital initiates coverage on Mama's Creations (MAMA) with a Buy rating and a $16 price target, citing the company's expanding national footprint, product innovation, and strong recent earnings as key growth catalysts in the fresh meal sector.
BMO Capital maintains its Outperform rating on Primo Brands Corporation (PRMB) despite lowering its price target, citing strong premium brand growth and a long-term recovery path for its direct-to-consumer segment.
Despite trading at a near 45% discount from December highs and showing early technical reversal signs, Cardano (ADA) is struggling to attract unified buying from large holders. On-chain data reveals fragmented whale behavior amid fading social interest and persistent structural risks.
Russian pipeline gas exports to Europe via TurkStream increased in January, even as the EU finalizes a sweeping ban and Moscow's overall sales hit a multi-decade low, underscoring the continent's complex and uneven energy transition.
Piper Sandler raises its price target on ImmunityBio, citing a near 700% surge in Anktiva sales and promising interim data from the QUILT trials that could support a major label expansion by 2027.
Baird raises its price target on Autoliv (ALV), citing resilience in the automotive safety giant's long-term outlook, even as near-term affordability concerns pressure the broader vehicle market.
Goldman Sachs and Baird reaffirm positive ratings on automotive technology supplier Visteon (VC), seeing significant upside potential even after modestly lowering price targets, driven by favorable sector outlook and growth in digital cockpit solutions.
Walmart is launching a cross-border shipping initiative early this year, enabling U.S.-based third-party sellers to directly reach consumers in Mexico and Canada, intensifying its e-commerce competition with Amazon.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
Analysts maintain a bullish outlook on Goodyear Tire & Rubber, citing strong potential in the replacement tire market and favorable inventory trends, with a median price target suggesting a 7% upside.
Aptiv PLC sees mixed but upwardly revised price targets from major analysts, with Piper Sandler upgrading the auto tech supplier to Overweight and naming it a top pick for 2026, citing its pragmatic strategy and attractive valuation.
Despite a recent sales miss, AutoZone (AZO) is doubling down on store growth, drawing mixed analyst reactions. JPMorgan remains bullish with an $4,100 price target, while Wolfe Research downgraded the stock, highlighting the complex landscape for the auto parts retailer.
Disney CEO Bob Iger confirmed that AI-generated videos from OpenAI's Sora will begin appearing on Disney+ within months, framing the move as an additive feature for short-form content while downplaying any ripple effects on the company's traditional film and TV pipeline.
Google is rolling out a significant update to its Chrome browser, embedding advanced Gemini AI capabilities directly into the user interface. The move signals a strategic push to make AI a central, everyday tool for web navigation and tasks.
As tech giants design their own AI processors, Broadcom's design expertise and TSMC's manufacturing might are creating a lucrative second front in the semiconductor boom, diversifying the winners beyond the GPU market leader.
The biotech company Grail has formally submitted its Galleri test for FDA premarket approval, a critical step that could unlock widespread insurance reimbursement and integrate the multi-cancer screening tool into mainstream preventive care.
Wall Street's top analysts made waves Monday with revised ratings on key stocks, highlighting a growing divergence in tech and retail outlooks as earnings season approaches.
Russia's premier cryptocurrency miner, BitRiver, faces insolvency proceedings as its CEO is placed under house arrest, marking a dramatic fall for a firm already crippled by international sanctions and mounting legal disputes.
A new report highlights how small and medium-sized businesses are leveraging AI, hyper-personalization, and sustainable practices not just to adapt, but to lead in a rapidly evolving marketplace.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
